icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
nNcszsNyv1szyZrC